Trials / Completed
CompletedNCT03985007
CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Chidamide, Decitabine Combined With Priming IAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is to investigate the therapeutic efficacy and side effect of chidamide, decitabine combined with priming IAG regimen for relapsed or refractroy acute myeloid leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CDIAG regimen | Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, decitabine 20mg/m2 intravenously daily for 5 days (d1-d5) and IAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 4-17; idarubicin, 5mg intravenously every other day on days 4, 6, 8, 10, 12, 14; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily on days 3-17. |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2020-12-31
- Completion
- 2021-03-16
- First posted
- 2019-06-13
- Last updated
- 2022-03-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03985007. Inclusion in this directory is not an endorsement.